A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Prior treatment

• Patients with the opportunity to be cured by surgery and radiotherapy.
• Received with concurrent chemoradiotherapy, adjuvant chemotherapy,neo- adjuvant chemotherapy within 4 weeks prior to randomization.
• Patients with other malignancies prior to randomization. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, transitional cell carcinoma of urothelial cancer, or carcinoma in situ (e.g. breast cancer) that have been cured are not excluded.
• Has not recovered adequately from toxicity and/or complications from surgery prior to randomization.
• Have received any investigational treatment in other clinical trials within 4 weeks prior to randomization.
• Has had an allogeneic tissue/solid organ/ hematopoietic stem cells transplant.

Other illness

• Has an active autoimmune disease that has required systemic treatment.
• With active serious infections.
• Subjects with HIV infection ,active hepatitis B virus infection, active hepatitis C virus infection,active tuberculosis infection,active syphilis .
• Has a contraindication or hypersensitivity to any component of cisplatin, carboplatin, paclitaxel, or bevacizumab.
• History of nervous system and mental disease. History of drug abuse.

Other

• Active central nervous system (CNS) metastasis.
• . .
• Pregnant or lactating women,or women may become pregnant during treatment.
• The patient is not suitable to participate the study in the opinion of the investigator.

• Signed the informed consent form.
• Women aged ≥ 18 and ≤ 75 years.
• ECOG of 0 or 1.
• Life expectancy ≥ 12 weeks.
• Cervical cancer patients with histologically confirmed PD-L1 positive (CPS ≥ 1),.The histological types include squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma.
• No prior systemic therapy for persistent, recurrent or metastatic (\[FIGO\] Stage IVB) disease,not amenable to curative surgery or concurrent chemoradiotherapy.
• At least one measurable tumor lesion per RECIST v1.1; lesions previously treated with radiotherapy or other loco-regional therapy are not considered as target lesions unless the lesion has unequivocal progression or the biopsy is obtained to confirm maligancy.
• Subjects must have adequate organ function.
• Female subjects of childbearing potential must have a negative serum pregnancy test prior to the first dose. Female subject of childbearing potential must use acceptable effective methods of contraception from screening and must agree to continue these precautions until 6 months after the last dose of study drug.